During the last session, Sangamo Therapeutics Inc (NASDAQ:SGMO)’s traded shares were 3.22 million, with the beta value of the company hitting 1.29. At the end of the trading day, the stock’s price was $1.15, reflecting an intraday gain of 1.77% or $0.02. The 52-week high for the SGMO share is $3.18, that puts it down -176.52 from that peak though still a striking 73.91% gain since the share price plummeted to a 52-week low of $0.30. The company’s market capitalization is $239.94M, and the average intraday trading volume over the past 10 days was 5.29 million shares, and the average trade volume was 10.63 million shares over the past three months.
Sangamo Therapeutics Inc (SGMO) received a consensus recommendation of Hold from analysts. That translates to a mean rating of 1.88. SGMO has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it.
Sangamo Therapeutics Inc (NASDAQ:SGMO) trade information
Sangamo Therapeutics Inc (SGMO) registered a 1.77% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.77% in intraday trading to $1.15, hitting a weekly high. The stock’s 5-day price performance is 12.20%, and it has moved by -51.06% in 30 days. Based on these gigs, the overall price performance for the year is 166.14%. The short interest in Sangamo Therapeutics Inc (NASDAQ:SGMO) is 21.52 million shares and it means that shorts have 2.26 day(s) to cover.
The consensus price target of analysts on Wall Street is $2.5, which implies an increase of 54.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 and $3 respectively. As a result, SGMO is trading at a discount of -160.87% off the target high and -73.91% off the low.
Sangamo Therapeutics Inc (SGMO) estimates and forecasts
Statistics show that Sangamo Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Sangamo Therapeutics Inc (SGMO) shares have gone up 191.07% during the last six months, with a year-to-date growth rate more than the industry average at 20.34% against 16.50.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -15.96%. While earnings are projected to return 68.32% in 2025.
SGMO Dividends
Sangamo Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Sangamo Therapeutics Inc (NASDAQ:SGMO)’s Major holders
Sangamo Therapeutics Inc insiders own 2.36% of total outstanding shares while institutional holders control 24.35%, with the float percentage being 24.94%. WASATCH ADVISORS LP is the largest shareholder of the company, while 123.0 institutions own stock in it. As of 2024-06-30, the company held over 20.09 million shares (or 11.1403% of all shares), a total value of $7.2 million in shares.
The next largest institutional holding, with 14.06 million shares, is of ARMISTICE CAPITAL, LLC’s that is approximately 7.7963% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $5.04 million.
